Literature DB >> 16706569

Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review.

Sylvia M C Vijgen1, Mirjam Hoogendoorn, Caroline A Baan, G Ardine de Wit, Wien Limburg, Talitha L Feenstra.   

Abstract

A systematic review of the literature was conducted to give an overview of economic evaluations of preventive interventions in type 2 diabetes mellitus. The interventions were sorted by type of preventive intervention (primary, secondary or tertiary) and by category (e.g. education, medication for hypertension). Several databases were searched for studies published between January 1990 and May 2004 on the three types of preventive intervention. For each study selected, inclusion of specific components from a standardised list of items, including quality, was recorded in a database. Summary tables were generated based on the database.A number of conclusions were drawn from this review. The most important was that strict blood pressure control was a more cost-effective intervention than less strict control, as shown by six studies reporting cost savings to very low costs per life-year gained. Primary and secondary prevention of type 2 diabetes were also highly cost effective, but these results were based on very few studies. Medications to reduce weight and hyperglycaemia together were cost effective compared with conventional interventions. Finally, the separate results regarding medications to reduce weight, hyperglycaemia and hypercholesterolaemia varied enormously, thus no conclusion could be drawn and further economic analysis is required.

Entities:  

Mesh:

Year:  2006        PMID: 16706569     DOI: 10.2165/00019053-200624050-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  93 in total

1.  Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt
Journal:  Diabetes Care       Date:  1998-04       Impact factor: 19.112

2.  Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.

Authors:  David E Kelley; George A Bray; F Xavier Pi-Sunyer; Samuel Klein; James Hill; John Miles; Priscilla Hollander
Journal:  Diabetes Care       Date:  2002-06       Impact factor: 19.112

3.  Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.

Authors: 
Journal:  JAMA       Date:  1996-11-06       Impact factor: 56.272

4.  Excessive mortality and causes of death in morbidly obese men.

Authors:  E J Drenick; G S Bale; F Seltzer; D G Johnson
Journal:  JAMA       Date:  1980-02-01       Impact factor: 56.272

5.  The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.

Authors:  B Jönsson; J R Cook; T R Pedersen
Journal:  Diabetologia       Date:  1999-11       Impact factor: 10.122

6.  A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.

Authors:  Mark Lamotte; Lieven Annemans; Aurelia Lefever; Myriam Nechelput; Johan Masure
Journal:  Diabetes Care       Date:  2002-02       Impact factor: 19.112

7.  The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.

Authors:  Roger A Rodby; Chion Fang Chiou; Jeff Borenstein; Allison Smitten; Nishan Sengupta; Andrew J Palmer; Stéphane Roze; Lieven Annemans; Teresa A Simon; Roland S Chen; Edmund J Lewis
Journal:  Clin Ther       Date:  2003-07       Impact factor: 3.393

8.  Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.

Authors:  Andreas Maetzel; Jörg Ruof; Melva Covington; Anne Wolf
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.

Authors:  P Koskinen; M Mänttäri; V Manninen; J K Huttunen; O P Heinonen; M H Frick
Journal:  Diabetes Care       Date:  1992-07       Impact factor: 19.112

10.  Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.

Authors:  John M Miles; Lawrence Leiter; Priscilla Hollander; Thomas Wadden; James W Anderson; Michael Doyle; John Foreyt; Louis Aronne; Samuel Klein
Journal:  Diabetes Care       Date:  2002-07       Impact factor: 19.112

View more
  14 in total

Review 1.  The prevention of type 2 diabetes.

Authors:  Jill P Crandall; William C Knowler; Steven E Kahn; David Marrero; Jose C Florez; George A Bray; Steven M Haffner; Mary Hoskin; David M Nathan
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-05-20

Review 2.  A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment.

Authors:  Jean-Eric Tarride; Robert Hopkins; Gord Blackhouse; James M Bowen; Matthias Bischof; Camilla Von Keyserlingk; Daria O'Reilly; Feng Xie; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Comparative effectiveness and child health.

Authors:  Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2012-08-01       Impact factor: 4.981

Review 4.  Economic Evaluation of Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force.

Authors:  Rui Li; Shuli Qu; Ping Zhang; Sajal Chattopadhyay; Edward W Gregg; Ann Albright; David Hopkins; Nicolaas P Pronk
Journal:  Ann Intern Med       Date:  2015-09-15       Impact factor: 25.391

Review 5.  Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review.

Authors:  Rui Li; Ping Zhang; Lawrence E Barker; Farah M Chowdhury; Xuanping Zhang
Journal:  Diabetes Care       Date:  2010-08       Impact factor: 17.152

Review 6.  Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases.

Authors:  Sanjib Saha; Ulf-G Gerdtham; Pia Johansson
Journal:  Int J Environ Res Public Health       Date:  2010-08-09       Impact factor: 3.390

7.  Hospital costs associated with pediatric burn injury.

Authors:  Matthew B Klein; William Hollingworth; Frederick P Rivara; C Bradley Kramer; Shelley W Askay; David M Heimbach; Nicole S Gibran
Journal:  J Burn Care Res       Date:  2008 Jul-Aug       Impact factor: 1.845

8.  2006 Ontario Survey on the Prevalence and Control of Hypertension (ON-BP): rationale and design of a community-based cross-sectional survey.

Authors:  J George Fodor; Frans H H Leenen; Eftyhia Helis; Penelope Turton
Journal:  Can J Cardiol       Date:  2008-06       Impact factor: 5.223

9.  Do lifestyle interventions work in developing countries? Findings from the Isfahan Healthy Heart Program in the Islamic Republic of Iran.

Authors:  Nizal Sarrafzadegan; Roya Kelishadi; Ahmad Esmaillzadeh; Noushin Mohammadifard; Katayoun Rabiei; Hamidreza Roohafza; Leila Azadbakht; Ahmad Bahonar; Gholamhossein Sadri; Ahmad Amani; Saeid Heidari; Hossein Malekafzali
Journal:  Bull World Health Organ       Date:  2009-01       Impact factor: 9.408

Review 10.  Exercise therapy in type 2 diabetes.

Authors:  Stephan F E Praet; Luc J C van Loon
Journal:  Acta Diabetol       Date:  2009-05-29       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.